Clinical trials: Renal Tumors
Renal Cell Carcinoma
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
This Phase 2a study will investigate the efficacy, safety and tolerability of ASONEP™ (sonepcizumab/LT1009) when administered intravenously once a week, every 4 weeks (or cycle), to subjects with refractory renal cell carcinoma…
- Trial name
- NCT01762033
- Testing
- ASONEP
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Lpath, Inc.
Renal Cell Cancer
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objectives: 1. To compare the overall survival of metastatic renal cell carcinoma (RCC) patients undergoing HLA-matched related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) using…
- Trial name
- NCT00429026
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma (Kidney Cancer)
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
- Trial name
- NCT07062549
- Testing
- 111In-XYIMSR-01
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pulmonary Embolism, Renal Cell Carcinoma
The Incidence of Pulmonary Embolism During Nephrectomy
Patients with renal carcinoma was reported at high incidence of perioperative pulmonary embolism from current study. The investigators aimed to determine the incidence and outcome of this group of patient in the tertiary-care…
- Conditions
- Pulmonary Embolism, Renal Cell Carcinoma, Nephrectomy
- Trial name
- NCT04402749
- Testing
- Nephrectomy
- Where
- Thailand
- Volunteers
- 416 people
- Sponsor
- Mahidol University
Metastatic Renal Cell Carcinoma
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases.
- Trial name
- NCT02406521
- Testing
- Pazopanib, Sorafenib, Radium-223
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Disorder Related to Renal Transplantation, Cancer
Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer
As early complications of transplantation (acute rejection and infections) were better controlled and that the survival of kidney transplants has increased, chronic complications of immunosuppression became increasing challenges.
- Trial name
- TRAK (NCT02843763)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Clear Cell Renal Carcinoma
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
This is an open label, multi-institutional, single arm study of dose escalation phase Ib cohort, followed by a phase II cohort of anti-PD-1 antibody MK-3475 in combination with bevacizumab.
- Trial name
- NCT02348008
- Testing
- MK-3475, Bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- Arkadiusz Z. Dudek, MD
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how…
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT00674193
- Testing
- pharmacological study, laboratory biomarker analysis
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Kidney Neoplasms
Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer
Renal cancer is frequent and its diagnosis mainly dependant on imaging. More than 50% of renal tumors are currently diagnosed without symptoms.
- Trial name
- CMM (NCT00491621)
- Testing
- surgery or biopsy of the kidney tumor
- Where
- 7 sites in France
- Volunteers
- 74 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Mild and Moderate Renal Impairment
Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
The purpose of this study is to determine the multiple dose pharmacokinetics of LCZ696 and its metabolites in subjects with mild to moderate renal impairment and to evaluate the safety of LCZ696 in this population.
- Trial name
- NCT01569815
- Testing
- LCZ696
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.
- Trial name
- NCT05319015
- Testing
- Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Neoplasms, Neoplasms, Glandular and Epithelial
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02897778
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Carcinoma, Renal Cell
Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma.
- Trial name
- CATChEz (NCT01545817)
- Testing
- Pazopanib followed by everolimus
- Where
- 15 sites in Australia, South Korea
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
This is a prospective, single-center, single-arm phase 2 study in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion.
- Trial name
- NCT05879497
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Renal Cell Carcinoma
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
The main goal of the research study is to determine whether treating renal cell cancer patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of kidney cancer that has spread to other parts of the…
- Trial name
- NCT01550367
- Testing
- Hydroxychloroquine, IL-2
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Leonard Appleman
Metastatic Renal Cell Cancer
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
The purpose of this study is to determine the maximum tolerated dose of RX-0201, up to a target dose of 250 mg/m^2/day, when given in combination with everolimus (Stage 1), and to assess the safety and efficacy of RX-0201 plus…
- Trial name
- NCT02089334
- Testing
- RX-0201
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Brain Tumor, Kidney Tumor
Engineering Immune Organoids to Study Pediatric Cancer
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
- Conditions
- Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma
- Trial name
- IMMUNEORGANOID (NCT05890781)
- Testing
- Skin biopsy, Fresh tumor sample, Blood sample
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
ccRCC
Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment
This study is being performed as a single-arm open-label study in order to provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with advanced ccRCC who have progressed…
- Trial name
- PRELUDE (NCT07460206)
- Testing
- Pembrolizumab 200 mg Q3W, Lenvatinib 20mg QD
- Volunteers
- 108 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Metastatic Renal Cell Cancer
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor.
- Trial name
- NCT02579811
- Testing
- Axitinib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a prospective, single-center, single-arm, comparative phase 2 study in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT05879471
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.